MLLT 6 maintains PD ‐L1 expression and mediates tumor immune resistance

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: MLLT 6 maintains PD ‐L1 expression and mediates tumor immune resistance ; volume:21 ; number:12 ; year:2020 ; extent:15
EMBO reports / European Molecular Biology Organization ; 21, Heft 12 (2020) (gesamt 15)

Creator: Sreevalsan, Sandeep
Döring, Marietta
Paszkowski-Rogacz, Maciej
Brux, Melanie
Blanck, Carolina
Meyer, Marten
Momburg, Frank
Buchholz, Frank
Theis, Mirko

DOI: 10.15252/embr.202050155

URN: urn:nbn:de:101:1-2022070408300690682997

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sreevalsan, Sandeep
Döring, Marietta
Paszkowski-Rogacz, Maciej
Brux, Melanie
Blanck, Carolina
Meyer, Marten
Momburg, Frank
Buchholz, Frank
Theis, Mirko

Other Objects (12)

NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury

IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury

IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury

IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

MLLT 6 maintains PD ‐L1 expression and mediates tumor immune resistance

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury

IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury

IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury

IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells

STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Related objects

Reset password